CHICAGO — An experimental drug shows the ability to more than double a person’s good cholesterol score, potentially filling a huge gap in cardiovascular care, scientists report. If the findings hold up in a larger trial, the drug, called anacetrapib, stands poised to become the best medication yet for boosting levels of the heart-disease preventer HDL.
“This is a very exciting era we are entering,” said Christopher Cannon, a cardiologist at Harvard Medical School and Brigham and Women’s Hospital in Boston. He presented the findings at a meeting of the American Heart Association on November 17, the same day they appeared online in the New England Journal of Medicine.
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.